Skip to main content
Premium Trial:

Request an Annual Quote

University of Utah Licenses Omicia's Opal for Genomic Interpretation

Premium

Omicia and the University of Utah said this week that they have signed a two-year licensing agreement that allows researchers involved in the Utah Genome Project use Opal, Omicia's platform for analyzing genomics in research and clinical applications, to analyze disease causing variants.

The Utah Genome Project is a large-scale, genome sequencing and analysis initiative that aims to discover new disease-causing genes and develop more personalized testing and treatment procedures. Under the terms of the agreement, researchers and clinicians involved in the project will be able to use Opal on a cost-per-genome basis to identify variants that are associated with autoimmune and metabolic disorders and other ailments.

The financial details of the agreement were not disclosed.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.